Skip to content
Menu
May 20, 2024
OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension
Share this press release:
Document loads below this notification.
If you are not able to see the document below, please reload page.
×
Dismiss this alert.
Prev
Previous PR
Additional Press Releases
August 1, 2023
/
Press Release
OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD
March 14, 2023
/
Press Release
Powering Social Enterprise with Profit and Purpose: The Tandem Hybrid by Scott Boyer, Jeremy Gudauskas, and Mike Hamel
November 30, 2022
/
Press Release
OWP Pharmaceuticals Announces Patent Application for First Oral Liquid Formulation of Trazodone for Treatment of MDD
View All Press Releases
View All Press Releases
CloseMenu
About Us
Our Purpose
Our People
Leadership Team
Board of Directors
FAQs
Products
Subvenite Starter Kits
Lamotrigine Starter Kits
Roweepra IR
Our Future
Pipeline
News
Press Releases
Events
Connect
Careers
Contact Us
© 2024 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2024 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2024 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
